Theratechnologies (THTX) announced that its shareholders have approved the previously announced plan of arrangement under Chapter XVI – Division II of the Business Corporations Act involving CB Biotechnology, LLC, an affiliate of Future Pak, LLC. At the special meeting of shareholders of Theratechnologies held earlier on Friday, the arrangement resolution was approved by 97.44% of the votes cast by the holders of shares present in person or virtually or represented by proxy at the meeting, and by 97.43% of the votes cast by the holders of shares present in person or virtually or represented by proxy at the meeting, excluding the votes cast by the shareholders required to be excluded pursuant to Multilateral Instrument 61-101 – Protection of Minority Security Holders in Special Transactions. The proposed arrangement remains subject to certain customary closing conditions, including the issuance of a final order by the Superior Court of Quebec following the hearing expected to take place on September 16.
TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on THTX:
- Theratechnologies Launches EGRIFTA WR™ for HIV-Related Lipodystrophy
- Theratechnologies announces availability of EGRIFTA WR
- Theratechnologies Gains Support for Future Pak Acquisition
- Theratechnologies says ISS, Glass Lewis recommend vote ‘FOR’ Future Pak plan
- Theratechnologies Announces Acquisition by CB Biotechnology with Significant Shareholder Premium
